2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Pancreatic Neoplasms
3
Neoplasms
2
Disease
2
Spinal Cord Neoplasms
1
Rectal Neoplasms
1
Pleural Effusion
1
Pleural Diseases
1
Pituitary Neoplasms
1
Parkinson Disease
1
Pancreatitis, Chronic
1
Pancreatic carcinoma, familial
1
Nervous System Diseases
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Mesothelioma
1
Hereditary pancreatitis
1
Hematologic Diseases
1
Epilepsy
1
Diabetes Mellitus
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Cardiotoxicity
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Bone Marrow Diseases
1
Interventions
Imatinib Mesylate
5
ruxolitinib
4
ponatinib
4
nilotinib
4
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
4
Azacitidine
3
fludarabine phosphate
2
fludarabine
2
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Cyclophosphamide
2
Busulfan
2
Bone Marrow Transplantation
2
spartalizumab
1
sonidegib
1
simtuzumab
1
sabatolimab
1
pembrolizumab
1
ibrutinib
1
bosutinib
1
Zoledronic Acid
1
Watchful Waiting
1
Sertraline
1
SCIO-469
1
Quality of Life
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bone Marrow Diseases
×
Clinical Laboratory Techniques
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled